| abstract |
Glucagon peptide analogs are described, which have been modified to be resistant to cleavage and inactivation by dipeptidylpeptidase IV (DPP-IV) and to increase the in vivo half-life of the peptide analog while allowing the peptide analog to have relatively agonist activity. balanced on glucagon-like peptide 1 (GLP-1) and glucagon receptor (GCG), and the use of such GLP-1 receptor / GCG receptor coagonists for the treatment of metabolic disorders such as diabetes, nonalcoholic hepatic hesteatosis (NAFLD), nonalcoholic steatohepatitis (NASH) and obesity. |